Loading…
Parnax Lab (BSE 506128)₹117.10−4.33%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Parnax Lab reported sales of ₹56.79 Cr, up 6.4% from Jun 2025, and net profit of ₹0.44 Cr, down 86.6% year on year. For the year to Mar 2026, sales were ₹249 Cr and net profit ₹12.05 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.63 | 50.97 | 46.36 | 50.07 | 48.31 | 40.19 | 49.00 | 53.37 | 62.53 | 62.93 | 69.64 | 56.79 |
| Expenses | 37.35 | 45.04 | 40.59 | 41.55 | 41.13 | 35.96 | 42.44 | 45.98 | 54.57 | 56.14 | 64.76 | 52.53 |
| Operating Profit | 5.30 | 5.98 | 5.80 | 8.63 | 7.25 | 4.28 | 6.64 | 7.46 | 8.09 | 6.86 | 4.89 | 4.32 |
| OPM % | 12.4% | 11.7% | 12.5% | 17.2% | 14.9% | 10.6% | 13.5% | 13.9% | 12.9% | 10.9% | 7.0% | 7.6% |
| Other Income | 0.23 | 0.11 | 0.26 | 0.12 | 0.96 | 0.20 | 0.44 | 0.19 | 0.64 | −0.18 | 1.77 | 0.16 |
| Interest | 1.44 | 1.36 | 1.42 | 1.49 | 1.39 | 1.24 | 1.27 | 1.23 | 1.41 | 1.48 | 1.60 | 1.63 |
| Depreciation | 1.73 | 1.77 | 1.83 | 1.82 | 1.93 | 1.78 | 1.82 | 1.93 | 2.09 | 1.95 | 2.03 | 2.21 |
| Profit before tax | 2.35 | 2.95 | 2.80 | 5.41 | 4.88 | 1.45 | 3.96 | 4.47 | 5.22 | 3.26 | 3.00 | 0.61 |
| Tax % | 20.0% | 25.7% | 19.3% | 26.3% | 29.7% | 16.6% | 26.0% | 26.4% | 30.3% | 16.5% | 27.0% | 28.3% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 |
| Net Profit | 1.88 | 2.19 | 2.25 | 4.01 | 3.43 | 1.22 | 2.94 | 3.29 | 3.63 | 2.72 | 2.20 | 0.44 |
| EPS (Rs) | 1.62 | 1.91 | 1.96 | 3.48 | 2.98 | 1.06 | 2.55 | 2.84 | 3.17 | 2.35 | 1.91 | 0.38 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.97 | 94.93 | 106 | 109 | 94.98 | 89.90 | 163 | 168 | 189 | 188 | 249 | 252 |
| Expenses | 61.08 | 81.99 | 95.13 | 99.01 | 89.12 | 80.03 | 140 | 145 | 165 | 161 | 221 | 228 |
| Operating Profit | 10.02 | 13.02 | 10.01 | 10.02 | 6.01 | 10.01 | 23.04 | 23.03 | 24.05 | 27.06 | 27.05 | 24.16 |
| OPM % | 14.0% | 14.0% | 10.0% | 9.0% | 7.0% | 11.0% | 14.0% | 14.0% | 12.0% | 14.0% | 11.0% | 9.6% |
| Other Income | 1.01 | 0.00 | 1.01 | 2.01 | 1.01 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 2.01 | 2.39 |
| Interest | 4.01 | 5.01 | 4.01 | 4.01 | 5.01 | 4.99 | 4.99 | 4.99 | 5.01 | 4.99 | 5.99 | 6.12 |
| Depreciation | 2.99 | 3.99 | 3.99 | 3.99 | 3.99 | 4.99 | 5.99 | 6.98 | 6.98 | 6.98 | 7.98 | 8.28 |
| Profit before tax | 3.01 | 5.01 | 3.01 | 5.01 | −2.01 | 0.00 | 12.01 | 12.02 | 12.01 | 16.01 | 16.02 | 12.09 |
| Tax % | 28.0% | 21.9% | 64.9% | 27.9% | 47.9% | 349.9% | 32.9% | 30.0% | 19.9% | 26.0% | 25.9% | — |
| Exceptional items | 0.00 | 0.00 | −0.09 | 0.00 | 0.00 | 0.02 | 0.00 | 0.02 | 0.03 | −0.20 | −1.03 | −1.01 |
| Net Profit | 3.01 | 4.02 | 1.01 | 3.01 | −3.01 | 0.00 | 8.04 | 9.04 | 10.03 | 12.06 | 12.05 | 8.99 |
| EPS (Rs) | 2.96 | 4.34 | 1.24 | 3.89 | −3.41 | −0.41 | 8.39 | 7.52 | 8.38 | 10.04 | 10.27 | 7.81 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 10.04 | 11.05 | 11.04 | 11.04 | 11.05 |
| Reserves | 17.05 | 19.07 | 23.07 | 24.08 | 27.08 | 24.09 | 24.08 | 38.11 | 51.20 | 60.14 | 72.25 | 84.32 |
| Borrowings | 41.08 | 42.06 | 39.09 | 37.09 | 42.10 | 51.10 | 59.10 | 69.10 | 55.13 | 81.13 | 70.14 | 83.11 |
| Other Liabilities | 17.08 | 10.05 | 15.06 | 18.00 | 17.08 | 23.00 | 15.07 | 36.11 | 28.05 | 38.11 | 36.99 | 50.14 |
| Total Liabilities | 83.24 | 79.21 | 86.25 | 87.20 | 95.29 | 107 | 106 | 153 | 145 | 190 | 190 | 229 |
| Fixed Assets | 36.10 | 38.11 | 47.13 | 44.10 | 51.13 | 58.11 | 60.17 | 72.19 | 77.20 | 89.20 | 88.23 | 115 |
| CWIP | 0.99 | 1.99 | 0.00 | 0.00 | 0.00 | 2.99 | 4.99 | 2.99 | 1.99 | 20.95 | 28.96 | 10.98 |
| Investments | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 45.14 | 38.10 | 38.12 | 43.10 | 43.16 | 46.12 | 41.12 | 78.18 | 66.24 | 80.27 | 72.23 | 101 |
| Inventories | 7.04 | 6.64 | 7.95 | 7.68 | 8.48 | 11.16 | 10.80 | 19.94 | 21.72 | 29.95 | 25.79 | 36.23 |
| Trade receivables | 23.53 | 19.45 | 18.71 | 18.69 | 19.22 | 23.11 | 16.75 | 38.16 | 27.96 | 32.62 | 30.80 | 37.87 |
| Cash & equivalents | 2.35 | 0.37 | 1.12 | 1.60 | 0.59 | 1.29 | 1.26 | 5.77 | 2.77 | 1.87 | 2.67 | 2.25 |
| Total Assets | 83.24 | 79.21 | 86.25 | 87.20 | 95.29 | 107 | 106 | 153 | 145 | 190 | 190 | 229 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 2.99 | 15.95 | 12.96 | 8.97 | 8.96 | 5.98 | 8.97 | 20.94 | 15.95 | 31.87 | 7.98 |
| Cash from investing activity | −4.02 | −6.02 | −10.03 | −5.02 | −11.04 | −13.05 | −7.03 | −16.06 | −10.03 | −32.11 | −16.05 | −16.05 |
| Cash from financing activity | 5.99 | 0.99 | −4.99 | −6.99 | 0.99 | 4.99 | 0.00 | 11.98 | −13.99 | 14.97 | −15.98 | 7.98 |
| Net cash flow | 0.99 | −1.99 | 0.00 | 0.99 | −0.99 | 0.00 | 0.00 | 3.99 | −3.01 | −0.99 | 0.00 | 0.00 |
| Capex | 3.78 | 6.12 | 10.82 | 5.22 | 11.31 | 13.16 | 4.53 | 17.80 | 11.26 | 14.13 | 9.73 | 35.40 |
| Free cash flow | −3.99 | −2.99 | 4.98 | 7.98 | −2.99 | −3.99 | 0.00 | −7.97 | 10.98 | −15.95 | 15.95 | −8.98 |
| CFO / OP % | 15.0% | 46.0% | 134.0% | 134.0% | 99.0% | 153.0% | 71.0% | 38.0% | 103.0% | 79.0% | 130.0% | 42.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 85 | 101 | 73 | 66 | 65 | 89 | 69 | 86 | 62 | 64 | 61 | 57 |
| Inventory days | 38 | 64 | 50 | 45 | 52 | 76 | 80 | 73 | 79 | 94 | 87 | 90 |
| Days payable | 52 | 31 | 49 | 46 | 45 | 75 | 47 | 82 | 54 | 75 | 73 | 81 |
| Cash conversion cycle | 71 | 134 | 74 | 64 | 72 | 90 | 102 | 77 | 86 | 83 | 75 | 65 |
| Working capital days | 17 | 8 | −25 | −7 | 0 | −30 | −65 | −34 | −18 | −22 | −23 | −10 |
| ROCE % | 16.0% | 11.0% | 14.0% | 11.0% | 12.0% | 3.0% | 6.0% | 17.0% | 15.0% | 13.0% | 14.0% | 14.0% |
For the Jun 2026 quarter, Parnax Lab reported sales of ₹56.79 Cr, up 6.4% year on year and net profit of ₹0.44 Cr, down 86.6% year on year. The operating margin was 7.6%.
Parnax Lab's sales for the year to Mar 2026 were ₹249 Cr; over the last twelve months they were ₹252 Cr.
Net profit for the year to Mar 2026 was ₹12.05 Cr, and ₹8.99 Cr over the last twelve months. Earnings per share over the same trailing period were ₹7.81.
Parnax Lab reported borrowings of ₹83.11 Cr at Mar 2026, against cash and equivalents of ₹2.25 Cr.
Cash from operations was ₹7.98 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹8.98 Cr.